Last updated: February 13, 2026
What Is the Current Market Status of NDC 00131-2477?
NDC 00131-2477 refers to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor approved by the FDA for treating rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions. It generated approximately $1.6 billion in U.S. sales in 2022, with a year-over-year growth rate of 4.7% (IQVIA). Its market share among JAK inhibitors remains dominant, although competition has increased.
How Does the Market for Tofacitinib Compare to Other JAK Inhibitors?
| Drug |
Brand Name |
Indications |
2022 U.S. Sales |
Market Share (2022) |
| Tofacitinib |
Xeljanz |
RA, psoriatic arthritis, UC |
$1.6B |
52% |
| Upadacitinib |
Rinvoq |
RA, UC, Crohn’s disease |
$1.2B |
39% |
| Filgotinib |
Gilead |
Clinical trials |
Limited sales |
N/A |
| Baricitinib |
Olumiant |
RA |
Estimated $400M |
9% |
Xeljanz maintains the largest share but faces rising competition from Rinvoq, which is growing faster in certain indications.
What Are the Key Drivers and Barriers in the Market?
Drivers:
- Increased Diagnosis: Rising prevalence of autoimmune diseases, notably RA and UC, expands potential patient pools.
- Expanding Indications: Approval for additional conditions like ulcerative colitis increases sales opportunities.
- Pipeline Developments: Clinical trials for new indications may solidify future revenue streams.
Barriers:
- Safety Concerns: Risks of infections and blood clots have led to warnings, possibly affecting prescribing patterns.
- Pricing and Reimbursement: High medication costs lead to scrutiny by payers, affecting access.
- Patent Expiration Risks: Patent protections for Xeljanz expire in 2027–2029 in key markets, opening pathways for generics.
What Are the Price Trends and Projections?
Current Pricing
- List Price: Approximately $4,400 per month for a typical dose (GoodRx).
- Average Wholesale Price (AWP): Slightly higher, used as a benchmark for negotiations.
- Net Price: Estimated 30–50% lower than list price after discounts and rebates.
Price Trends
- Over the past 5 years, list prices have increased annually by 3–4%. Discounts and rebates insulate payers but vary significantly among regions and payers.
Price Projections (Next 5 Years)
| Year |
Estimated List Price |
Key Factors Affecting Price |
| 2023 |
$4,400/month |
Stable, driven by inflation and research costs |
| 2024 |
$4,530/month |
Potential slight increase due to new indications or formulations |
| 2025 |
$4,670/month |
Patent expiration approaches; generic entry anticipated in select markets |
| 2026 |
$4,805/month |
Generic competitors likely to influence net prices |
| 2027 |
$4,935/month |
Introduction of generics could reduce net price by 50% in some markets |
Implications
- The introduction of generics post-patent expiry will significantly lower revenues and pricing.
- Manufacturers may consider formulation or delivery innovations to maintain margin.
What Are the Regulatory and Competitive Risks?
- Regulatory Scrutiny: Warnings from FDA regarding safety profile could influence label updates, impacting sales.
- Market Competition: Rinvoq gains market share rapidly; biosimilar competition is expected after patent expiry.
- Patent Litigation: Patent challenges and legal disputes could delay generic entry or reduce generics' market share.
Summary
Xeljanz (NDC 00131-2477) is a leading treatment in the autoimmune space with a strong revenue base. Market growth is steady, driven by expanding indications, but faces increasing competition and safety concerns. Pricing trends reflect high list prices with significant discounts. Post-2027, generic entry is expected to exert downward pressure on prices and sales.
Key Takeaways
- Xeljanz led the JAK inhibitor market with $1.6 billion in 2022 U.S. sales.
- Market share favors Xeljanz but increasingly shifts toward Rinvoq.
- Prices are rising modestly; generics could cut prices by half after patent expiry.
- Competition, safety warnings, and patent cliffs remain critical factors.
- The next five years will see fundamental changes in pricing and market dynamics.
FAQs
1. When are the patents for Xeljanz set to expire?
Market-specific patent expiries range from 2027 to 2029, with some secondary patents possibly extending exclusivity.
2. How does the safety profile affect the market?
Warnings about infections and blood clots have led clinicians to monitor patients closely, slightly limiting new prescriptions.
3. Are biosimilars likely for Xeljanz?
Biosimilars are less common than generics and depend on patent challenges. No biosimilars are approved in the U.S. yet.
4. What is the potential impact of new indications on sales?
Expanding to conditions like severe ulcerative colitis increases the patient population and revenue streams.
5. How do reimbursement policies influence prices?
Payers negotiate significant rebates and discounts, which reduces net prices but complicates pricing forecasts.
Sources:
[1] IQVIA 2022 Pharmaceutical Market Data
[2] GoodRx Pricing Data
[3] FDA Label and Safety Warnings
[4] Patent Expiry and Litigation Reports
